Home » Newsletters » BioWorld Science

BioWorld Science

March 7, 2014

View Archived Issues

Stemnion divulges new cell compositions for neurological disorders

Arno Therapeutics signs license for oncology diagnostic technique

Hawaii Biotech awarded DoD contract to develop anti-botulism drugs

New preclinical study to evaluate Cynata's Cymerus MSC product for GvHD

Cellceutix compounds investigated in animal models of Gram-negative bacterial infections

Healios and Dainippon Sumitomo Pharma establish SighRegen

ARRY-502 shows promising safety and efficacy in patients with asthma

Phase III results show brexpiprazole to be well tolerated as adjunctive therapy for MDD patients

Data presented for ustekinumab for the treatment of anti-TNF-resistant Crohn's disease

Eleven Biotherapeutics updates on EBI-005 development

Alkermes begins pivotal program for ALKS-5461 in major depressive disorder

FDA clears Alcobra's IND for metadoxine extended release

Albireo begins phase II trial of A-3384

Xolair approved in Europe for chronic spontaneous urticaria

Alnylam Pharmaceuticals closes acquisition with Sirna Therapeutics

Omeros reports additional data from phase IIa trial of OMS-824

diaDexus forms U.S. licensing biomarker deal with Thermo Fisher Scientific

Ono Pharmaceutical and Japanese universities establish collaborative research network

FDA approves Aveed as a testosterone replacement therapy

NeoStem forms research agreement with affiliate of Harvard Medical School

Roche prepares new CDK8 inhibitors for cancer

Ardelyx and AstraZeneca patent new NHE-3 inhibitors for gastrointestinal disorders

Japanese approval sought for E Keppra monotherapy for partial-onset seizures

Scientists in Japan disclose new agents for obesity and other disorders

Incyte reports topline results from phase III ruxolitinib study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...